Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

BBI-355

Small molecule · Inhibitor of checkpoint kinase 1 (Chk1) (CHEK1) · developed by Boundless Bio

Phase 1 Most advanced trial (none active)
BOLD Developer
1 Registered trials

What is BBI-355?

BBI-355 is an orally bioavailable small molecule that selectively binds and inhibits checkpoint kinase 1 (Chk1), an ATP-dependent serine/threonine kinase involved in cell cycle checkpoint control and DNA repair. It is being studied in multiple solid tumors, including triple negative breast cancer, ovarian, endometrial, head and neck, and small cell lung cancers.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Targets
checkpoint kinase 1 (Chk1) (CHEK1)
Mechanism
Inhibitor of checkpoint kinase 1 (Chk1) (CHEK1)
Pathways
DNA damage repair, cell cycle checkpoint control, apoptosis
Therapy area
Oncology
Developer
Boundless Bio, Inc. (BOLD)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05827614 Phase 1 Triple Negative Breast Cancer (TNBC) Terminated BOLD

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Anogenital CancerCervical Squamous Cell CarcinomaCutaneous Squamous Cell Carcinoma (CSCC)ER+ Breast CancerHead and Neck (HNSCC)High Grade Endometrial CarcinomaHigh Grade Serous Ovarian CarcinomaLeiomyosarcoma (LMS)Pancreatic Cancer MetastaticSmall Cell Lung CancerTriple Negative Breast Cancer (TNBC)Undifferentiated Pleomorphic Sarcoma (UPS)

Other drugs acting on CHEK1

More from Boundless Bio

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the BOLD page.

Follow BOLD, the company behind BBI-355

See BOLD's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

BOLD catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.